NovaBay Pharmaceuticals (NBY) to Release Quarterly Earnings on Thursday

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) is projected to announce its Q4 2025 results after the market closes on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $3.00 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

NovaBay Pharmaceuticals Trading Down 5.9%

NovaBay Pharmaceuticals stock opened at $1.28 on Thursday. NovaBay Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $99.75. The stock has a market cap of $33.18 million, a P/E ratio of -0.13 and a beta of 0.25. The stock has a 50 day moving average of $16.02 and a 200-day moving average of $13.05.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its position in shares of NovaBay Pharmaceuticals by 2,331.7% in the 4th quarter. Geode Capital Management LLC now owns 1,257,705 shares of the biopharmaceutical company’s stock worth $7,098,000 after purchasing an additional 1,205,984 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new position in shares of NovaBay Pharmaceuticals during the fourth quarter worth about $526,000. State Street Corp lifted its position in shares of NovaBay Pharmaceuticals by 970.5% during the fourth quarter. State Street Corp now owns 313,703 shares of the biopharmaceutical company’s stock worth $1,769,000 after purchasing an additional 284,400 shares during the last quarter. Jane Street Group LLC acquired a new position in NovaBay Pharmaceuticals in the fourth quarter worth about $395,000. Finally, Goldman Sachs Group Inc. acquired a new position in NovaBay Pharmaceuticals in the fourth quarter worth about $588,000. 23.25% of the stock is currently owned by institutional investors.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.